Autophagic and Apoptotic Pathways as Targets for Chemotherapy in Glioblastoma.

作者: Cristina Trejo-Solís , Norma Serrano-Garcia , Ángel Escamilla-Ramírez , Rosa Castillo-Rodríguez , Dolores Jimenez-Farfan

DOI: 10.3390/IJMS19123773

关键词:

摘要: Glioblastoma multiforme is the most malignant and aggressive type of brain tumor, with a mean life expectancy less than 15 months. This due in part to high resistance apoptosis moderate resistant autophagic cell death glioblastoma cells, poor therapeutic response conventional therapies. Autophagic represents an alternative mechanism overcome pro-apoptosis-related Nevertheless, induction plays major conceptual role several experimental studies develop novel therapies against tumors. In this review, we outline different components apoptotic pathways explore mechanisms these cells. Finally, discuss drugs clinical preclinical use that interfere survival, proliferation, angiogenesis, migration, invasion, favoring autophagy, or inhibition latter leading death, as well their potential glioma, examine new perspectives promising research field.

参考文章(343)
Joseph George, Naren L. Banik, Swapan K. Ray, Molecular Mechanisms of Taxol for Induction of Cell Death in Glioblastomas Springer, New York, NY. pp. 283- 298 ,(2010) , 10.1007/978-1-4419-0410-2_14
Paul Christos, John A Boockvar, Susan C Pannullo, Lynn Mubita, Apostolos J Tsiouris, Ehud Lavi, Cody D Schlaff, Ronald Scheff, Benjamin Shin, Rachel Kaplan, Kartik Kesavabhotla, Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma. Journal of Experimental Therapeutics and Oncology. ,vol. 10, pp. 71- 81 ,(2012)
Hélène Burckel, Elodie Josset, Georges Noël, Pierre Bischoff, The mTOR Inhibitor RAD001 Potentiates Autophagic Cell Death Induced by Temozolomide in a Glioblastoma Cell Line Anticancer Research. ,vol. 33, pp. 1845- 1851 ,(2013)
John D Hainsworth, Gregg C Shepard, David R Spigel, Kent C Shih, Brett T Brinker, Guy W Tillinghast, Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. Clinical advances in hematology & oncology. ,vol. 10, pp. 240- 246 ,(2012)
Sudhir Gupta, Molecular steps of cell suicide: an insight into immune senescence. Journal of Clinical Immunology. ,vol. 20, pp. 229- 239 ,(2000) , 10.1023/A:1006653917314
Carsten Scaffidi, Frank C. Kischkel, Peter H. Krammer, Marcus E. Peter, Analysis of the CD95 (APO-1/Fas) death-inducing signaling complex by high-resolution two-dimensional gel electrophoresis. Methods in Enzymology. ,vol. 322, pp. 363- 373 ,(2000) , 10.1016/S0076-6879(00)22033-8
Marcelo Budke, Alberto Isla Guerrero, Carlos Pérez López, Marcelino Pérez Álvarez, Antonio García Grande, M. J. Bello, J. Rey, A comparative study of the treatment of high grade gliomas Revista De Neurologia. ,vol. 37, pp. 912- 916 ,(2003) , 10.33588/RN.3710.2003014
Peter Bushunow, Marcus M. Reidenberg, John Wasenko, Jeffrey Winfield, Beverly Lorenzo, Sheila Lemke, Benjamin Himpler, Robert Corona, Thomas Coyle, Gossypol treatment of recurrent adult malignant gliomas. Journal of Neuro-oncology. ,vol. 43, pp. 79- 86 ,(1999) , 10.1023/A:1006267902186
M. Cristina Moroni, Emma S. Hickman, Eros Lazzerini Denchi, Greta Caprara, Elena Colli, Francesco Cecconi, Heiko Müller, Kristian Helin, Apaf-1 is a transcriptional target for E2F and p53 Nature Cell Biology. ,vol. 3, pp. 552- 558 ,(2001) , 10.1038/35078527